CHICAGO, March 24, 2020 /PRNewswire/ -- Hillrom
(NYSE: HRC) today announced actions it is taking to support
customers and caregivers with critical care products necessary to
meet COVID-19 patient needs.
Hillrom's business operations continue with no material
interruption as global demand for several critical products has
grown substantially. The company is working to significantly ramp
up production of these products, with the goal of more than
doubling capacity in the following areas:
- Respiratory health, especially Life2000®, a non-invasive
ventilator currently approved in the U.S. that is portable,
lightweight and ideal for treating patients with mild to moderate
respiratory distress across various acute care settings, including
the emergency department, med-surg and post-ventilator weaning
support. Expanded use of non-invasive ventilation can free up
capacity for invasive ventilators for the most serious COVID-19
patients. Hillrom is working to increase its production capacity of
Life2000 five-fold on an annualized basis.
- ICU and med-surg unit smart beds, including the
company's Progressa® ICU bed, Centrella® Smart+ bed, and, for
international markets, the Hillrom® 900 and Hillrom® 900
Accella™.
- Patient monitoring and diagnostics, including the
company's Connex® and Spot Vital Signs® monitors as well as
physical assessment tools and consumables, including thermometry,
probe covers and blood pressure devices and cuffs.
"We are committed to scaling production as rapidly as we can to
meet the challenges the world is facing with COVID-19," said
Hillrom President and CEO John
Groetelaars. "Hillrom's critical care, vitals monitoring and
respiratory products can help caregivers and patients as
coronavirus continues to cause severe illness around the world. We
are focused on our employees' health and safety, and on ensuring
that our products are available when and where our customers and
patients need them."
Hillrom relies on a global supply chain and has a balanced
global manufacturing footprint, with manufacturing facilities
located in the U.S., Europe,
Asia and Mexico. The company has seen no material
disruption in its supply chain to date. Hillrom's suppliers are a
critical component of successfully meeting customer demand, and the
company is working with its supply chain partners to minimize any
potential disruption.
Given the fluidity of the coronavirus pandemic, Hillrom will
continue to monitor and assess business operations, and will
provide additional information as appropriate.
About Hillrom
Hillrom is a global medical technology leader whose 10,000
employees have a single purpose: enhancing outcomes for patients
and their caregivers by advancing connected care. Around the world,
our innovations touch over 7 million patients each day. They help
enable earlier diagnosis and treatment, optimize surgical
efficiency and accelerate patient recovery while simplifying
clinical communication and shifting care closer to home. We
make these outcomes possible through connected smart beds, patient
lifts, patient assessment and monitoring technologies, caregiver
collaboration tools, respiratory health devices, advanced operating
room equipment and more, delivering actionable, real-time insights
at the point of care. Learn more at hillrom.com.
Disclosure Regarding Forward-Looking Statements
Certain statements herein contain forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended, regarding the company's future plans,
objectives, beliefs, expectations, representations and projections.
It is important to note that forward-looking statements are not
guarantees of future performance, and the company's actual results
could differ materially from those set forth in any forward-looking
statements, including but not limited to, the potential risks
and uncertainties relating to the ultimate geographic spread of
COVID-19, the severity of the disease, the duration of the COVID-19
outbreak, actions that may be taken by governmental authorities to
contain the COVID-19 outbreak or to treat its impact, the potential
negative impacts of COVID-19 on the global economy and the
company's sourcing, and the overall impact of the COVID-19 outbreak
on the company's business, results of operations and financial
condition. For a more in-depth discussion of other factors that
could cause actual results to differ from those contained in
forward-looking statements, see the discussions under the heading
"Risk Factors" in the company's previously filed most recent Annual
Report on Form 10-K and subsequent Quarterly Reports on Form
10-Q. The company assumes no obligation to update or revise
any forward-looking statements, unless required by law.
CONTACT
INFORMATION
|
|
Investor
Relations
|
|
|
Contact:
|
Mary Kay Ladone,
Senior Vice President, Corporate Development, Strategy and Investor
Relations
|
Contact:
|
Lorna Williams,
Executive Director, Investor Relations and Strategy
|
Phone:
|
312-819-9387
|
Phone:
|
312-233-7799
|
Email:
|
marykay.ladone@hillrom.com
|
Email:
|
lorna.williams@hillrom.com
|
|
|
|
Media
|
|
|
Contact:
|
Howard Karesh, Vice
President, Corporate Communications
|
|
|
Phone:
|
312-819-7268
|
|
|
Email:
|
howard.karesh@hillrom.com
|
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hillrom-more-than-doubles-production-of-critical-care-products-including-ventilators-hospital-beds-and-vitals-monitoring-devices-to-support-covid-19-response-301029228.html
SOURCE Hillrom